Abstract
In other cardiomyopathies, cardiac magnetic resonance imaging (CMR)-derived myocardial delayed enhancement (MDE), a marker of myocardial fibrosis, is a risk factor for sudden cardiac death (SCD). In Duchenne muscular dystrophy (DMD), the prognostic value of MDE for ventricular arrhythmias and death is unknown. This study aimed to evaluate associations between MDE and electrocardiographic (ECG) changes, ventricular remodeling, risk of arrhythmias, and death in DMD. This retrospective study included all subjects with DMD who had undergone a CMR between January 2006 and December 2011 and had available ECG and 24-h Holter records from the same period. Left ventricular (LV) MDE was semiquantitatively graded from 0 to 4. Comparisons of demographic and clinical characteristics between MDE and no-MDE groups were made. Cox regression analysis was performed to assess factors associated with death. This study investigated 32 boys with a median age of 13.8 years (range, 7.2–17.4 years) and found MDE present in 25 (78 %) of the boys. Compared with the no-MDE subjects, the MDE subjects were older (15.7 ± 3.3 vs 12.1 ± 4.8 years) and had a wider QT dispersion (QTd: 74 ± 30 vs 55 ± 33 ms), a higher incidence of ventricular tachycardia (40 vs 0 %), a lower LV ejection fraction (46 ± 12 vs 56 ± 9 %), a larger LV end-diastolic volume (124 ± 58 vs 68 ± 14 ml/m2), and a larger end-systolic volume (57 ± 29 vs 28 ± 10 ml/m2) (p < 0.05 for all). During the study period, six of the subjects (19 %) died. The factors associated with mortality were increased age, advanced grade of MDE, higher LV end-systolic volume, lower LV ejection fraction, use of beta-blockers, and ventricular tachycardia. Myocardial fibrosis detected by CMR is an independent predictor of adverse cardiac remodeling, ventricular arrhythmias, and death in DMD. Cardiac MRI using MDE can be applied as a screening tool to detect patients at risk for ventricular arrhythmias, more advanced disease, adverse LV remodeling, and death.
Similar content being viewed by others
References
Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, Lesser JR, Hanna CA, Udelson JE, Manning WJ, Maron MS (2008) Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 51:1369–1374. doi:10.1016/j.jacc.2007.11.071
Barr CS, Naas A, Freeman M, Lang CC, Struthers AD (1994) QT dispersion and sudden unexpected death in chronic heart failure. Lancet 343:327–329
Chenard AA, Becane HM, Tertrain F, de Kermadec JM, Weiss YA (1993) Ventricular arrhythmia in Duchenne muscular dystrophy: prevalence, significance, and prognosis. Neuromuscul Disord 3:201–206
Corrado G, Lissoni A, Beretta S, Terenghi L, Tadeo G, Foglia-Manzillo G, Tagliagambe LM, Spata M, Santarone M (2002) Prognostic value of electrocardiograms, ventricular late potentials, ventricular arrhythmias, and left ventricular systolic dysfunction in patients with Duchenne muscular dystrophy. Am J Cardiol 89:838–841
Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K (2002) Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 12:926–929
Finsterer J, Stollberger C (2003) The heart in human dystrophinopathies. Cardiology 99:1–19 68446
Frankel KA, Rosser RJ (1976) The pathology of the heart in progressive muscular dystrophy: epimyocardial fibrosis. Hum Pathol 7:375–386
Goldberg SJ, Stern LZ, Feldman L, Allen HD, Sahn DJ, Valdes-Cruz LM (1982) Serial two-dimensional echocardiography in Duchenne muscular dystrophy. Neurology 32:1101–1105
Jay V, Vajsar J (2001) The dystrophy of Duchenne. Lancet 357:550–552. doi:10.1016/S0140-6736(00)04052-6
Lapidos KA, Kakkar R, McNally EM (2004) The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res 94:1023–1031. doi:10.1161/01.RES.0000126574.61061.25
Linker NJ, Colonna P, Kekwick CA, Till J, Camm AJ, Ward DE (1992) Assessment of QT dispersion in symptomatic patients with congenital long QT syndromes. Am J Cardiol 69:634–638
Malik M, Batchvarov VN (2000) Measurement, interpretation, and clinical potential of QT dispersion. J Am Coll Cardiol 36:1749–1766
Moon JC, Reed E, Sheppard MN, Elkington AG, Ho SY, Burke M, Petrou M, Pennell DJ (2004) The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 43:2260–2264. doi:10.1016/j.jacc.2004.03.035
Moon JC, Mogensen J, Elliott PM, Smith GC, Elkington AG, Prasad SK, Pennell DJ, McKenna WJ (2005) Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. Heart 91:1036–1040. doi:10.1136/hrt.2004.041384
Nigro G, Comi LI, Politano L, Bain RJ (1990) The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 26:271–277
O’Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, Webb J, Kulkarni M, Dawson D, Sulaibeekh L, Chandrasekaran B, Bucciarelli-Ducci C, Pasquale F, Cowie MR, McKenna WJ, Sheppard MN, Elliott PM, Pennell DJ, Prasad SK (2010) Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 56:867–874. doi:10.1016/j.jacc.2010.05.010
Perloff JK (1984) Cardiac rhythm and conduction in Duchenne’s muscular dystrophy: a prospective study of 20 patients. J Am Coll Cardiol 3:1263–1268
Pichavant C, Aartsma-Rus A, Clemens PR, Davies KE, Dickson G, Takeda S, Wilton SD, Wolff JA, Wooddell CI, Xiao X, Tremblay JP (2011) Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol Ther 19:830–840. doi:10.1038/mt.2011.59
Politano L, Nigro G (2012) Treatment of dystrophinopathic cardiomyopathy: review of the literature and personal results. Acta Myol 31:24–30
Puchalski MD, Williams RV, Askovich B, Sower CT, Hor KH, Su JT, Pack N, Dibella E, Gottliebson WM (2009) Late gadolinium enhancement: precursor to cardiomyopathy in Duchenne muscular dystrophy? Int J Cardiovas Imag 25:57–63. doi:10.1007/s10554-008-9352-y
Silva MC, Meira ZM, Gurgel Giannetti J, da Silva MM, Campos AF, Barbosa Mde M, Starling Filho GM, Ferreira Rde A, Zatz M, Rochitte CE (2007) Myocardial delayed enhancement by magnetic resonance imaging in patients with muscular dystrophy. J Am Coll Cardiol 49:1874–1879. doi:10.1016/j.jacc.2006.10.078
Towbin JA (1998) The role of cytoskeletal proteins in cardiomyopathies. Curr Opin Cell Biol 10:131–139
van de Loo A, Arendts W, Hohnloser SH (1994) Variability of QT dispersion measurements in the surface electrocardiogram in patients with acute myocardial infarction and in normal subjects. Am J Cardiol 74:1113–1118
Wilson JM, Villareal RP, Hariharan R, Massumi A, Muthupillai R, Flamm SD (2002) Magnetic resonance imaging of myocardial fibrosis in hypertrophic cardiomyopathy. Tex Heart Inst J 29:176–180
Yanagisawa A, Miyagawa M, Yotsukura M, Tsuya T, Shirato C, Ishihara T, Aoyagi T, Ishikawa K (1992) The prevalence and prognostic significance of arrhythmias in Duchenne type muscular dystrophy. Am Heart J 124:1244–1250
Yotsukura M, Yamamoto A, Kajiwara T, Nishimura T, Sakata K, Ishihara T, Ishikawa K (1999) QT dispersion in patients with Duchenne-type progressive muscular dystrophy. Am Heart J 137(4 Pt 1):672–677
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Menon, S.C., Etheridge, S.P., Liesemer, K.N. et al. Predictive Value of Myocardial Delayed Enhancement in Duchenne Muscular Dystrophy. Pediatr Cardiol 35, 1279–1285 (2014). https://doi.org/10.1007/s00246-014-0929-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-014-0929-z